Tetrous, Inc., a regenerative medicine company, announced it was issued a patent (U.S. Patent Number 11,759,548) specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is currently available in the United States and Australia. EnFix RC changes the paradigm in rotator cuff surgery by enhancing healing at the tendon-to-bone interface, i.e., at the enthesis, where failure often occurs. The 100% demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity in a unique graft, while FormLok™ technology imparts shape retention to the device. The implant has minimal disruption to the current surgical technique.
The newly issued patent, titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair”, further augments Tetrous’ intellectual property portfolio, covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair. “We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent,” said Andy Carter, PhD, Tetrous’ Co-Founder, Director and co-inventor on the issued patent. “Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the next-generation enthesis repair market.”
Tetrous, Inc., a regenerative medicine company, announced it was issued a patent (U.S. Patent Number 11,759,548) specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RCâ„¢, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is...
Tetrous, Inc., a regenerative medicine company, announced it was issued a patent (U.S. Patent Number 11,759,548) specifically related to the EnFix family of demineralized cortical bone fiber implants and their method of manufacture.
EnFix RC™, the first product in the EnFix family, is a procedure-specific implant for rotator cuff repair. It is currently available in the United States and Australia. EnFix RC changes the paradigm in rotator cuff surgery by enhancing healing at the tendon-to-bone interface, i.e., at the enthesis, where failure often occurs. The 100% demineralized bone fiber (DBF) implants provide osteoinductivity and osteoconductivity in a unique graft, while FormLok™ technology imparts shape retention to the device. The implant has minimal disruption to the current surgical technique.
The newly issued patent, titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair”, further augments Tetrous’ intellectual property portfolio, covering demineralized cortical bone fiber implants, bone healing, and enhancement of tendon to bone repair. “We are pleased that the U.S. Patent Office has yet again recognized the uniqueness of our technology and has granted this additional patent,” said Andy Carter, PhD, Tetrous’ Co-Founder, Director and co-inventor on the issued patent. “Our growing intellectual property portfolio provides Tetrous a sustainable competitive advantage in the next-generation enthesis repair market.”
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
